- Home
- NMS vs SER Comparison
NMS vs SER Comparison
Compare NMS & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMS | SER |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.2M | 56.4M |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | NMS | SER |
|---|---|---|
| Price | $10.61 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 24.3K | ★ 66.8K |
| Earning Date | 01-01-0001 | 11-24-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $130,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.14 |
| 52 Week Low | $9.48 | $1.14 |
| 52 Week High | $12.50 | $4.26 |
Technical Indicators
Market Signals| Indicator | NMS | SER |
|---|---|---|
| Relative Strength Index (RSI) | 59.50 | 43.26 |
| Support Level | $10.03 | $1.59 |
| Resistance Level | $10.75 | $2.13 |
| Average True Range (ATR) | 0.18 | 0.32 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 71.77 | 33.33 |
Price Performance
Historical ComparisonAbout NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The company has Single operating segment.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.